Cancer Science & Therapy

GAMS van Dongen

Publications

• Research Article
  Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study
  Author(s): Mélanie Vaes, D Bron, DJ Vugts, M Paesmans, N Meuleman, G Ghanem, T Guiot, B Vanderlinden, K Thielemans, GAMS van Dongen, P Flamen and K MuylleMélanie Vaes, D Bron, DJ Vugts, M Paesmans, N Meuleman, G Ghanem, T Guiot, B Vanderlinden, K Thielemans, GAMS van Dongen, P Flamen and K Muylle
  
  Purpose: Both anti-CD20 antibodies (ibritumomab; ZEVALIN® and tositumomab; BEXXAR®) currently used for radioimmunotherapy of B cell non-Hodgkin’s lymphoma are murine immunoglobulins. The aim of this feasibility study was to evaluate the safety and efficacy of radioimmunotherapy with a human chimeric anti-CD20 antibody labelled with Yttrium-90 (90Y-rituximab) in patients with B cell lymphoma. Methods: Patients with CD20+ B-cell lymphoma in partial remission or with progressive disease after at least one line of therapy were included. 90Y-rituximab was administered according to a similar schedule as currently approved by the European Medicines Agency for the treatment with 90Y-ibritumomab tiuxetan (ZEVALIN®): a first infusion of rituximab 250 mg/m² is repeated one week later and directly followed by the injection of 90Y-ri.. Read More»
  DOI: 10.4172/1948-5956.1000173

  Abstract PDF